ABOUT CARDIUM: Business Strategy

Building upon our core products and product candidates, our strategic goal is to develop a portfolio of medical product candidates at various stages of development and secure additional financial resources to commercialize these products in a timely and effective manner. The key elements of our strategy are to:

• Commercialize through a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) our ExcellagenXL™ product candidate designed for use by physicians in patients with diabetic ulcers, venous ulcers, or other wounds, and consistent with Cardium’s overall business strategy, seek marketing partners in U.S. and internationally;
  
  
• Launch MedPodium™ Over-the-Counter Advanced Skin Care Line to be co-marketed with the Excellagen collagen-based platform;
  
  
• Initiate Matrix Phase 2/3 clinical study of Excellarate™, a topical gene-activated collagen-based gel for patients with chronic diabetic wounds and seek a strategic or financial partner to share remaining clinical development and commercialization costs;
  
  
• Initiate a Phase 2/3 clinical study (with adaptive study design) for Generx^®, a DNA based therapeutic for patients with coronary artery disease who are not optimal candidates for or do not have access to advanced surgical therapies such as angioplasty/stents and coronary artery by-pass surgery, for potential initial registration outside the U.S.; and
  
  
• Continue to review acquisitions of other companies and businesses, as well as licenses covering product opportunities and technologies on favorable economic terms consistent with Cardium’s long-term business strategy and track record.